P/E ratio for Ligand Pharmaceuticals (LGND)

P/E ratio history for Ligand Pharmaceuticals from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	21.3	-75.78%	🇺🇸 USA
Pfizer PFE	20.2	-77.12%	🇺🇸 USA
Eli Lilly LLY	39.9	-54.74%	🇺🇸 USA
Amgen AMGN	24.4	-72.27%	🇺🇸 USA
Baxter BAX	-25.2	-128.66%	🇺🇸 USA
Merck MRK	15.6	-82.25%	🇺🇸 USA
Bristol-Myers Squibb BMY	19.6	-77.78%	🇺🇸 USA
GSK plc GSK	13.9	-84.22%	🇬🇧 UK
Spectrum Pharmaceuticals SPPI	-2.86	-103.25%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.